Letrozol Viatris

Letrozole, the active ingredient in Letrozol Viatris, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is used in the management of estrogen‑positive breast cancer in postmenopausal women, as approved in the European Union.

GNH USA supplies Letrozol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality and regulatory conformity for global distribution. The product conforms to EU pharmaceutical standards and is marketed across European Union member states.

Letrozole acts on the estrogen synthesis pathway and is employed in hormone‑dependent breast cancer therapy. - Adjuvant treatment of estrogen‑receptor‑positive early breast cancer: lowers risk of recurrence after surgery. - Metastatic breast cancer in postmenopausal women: helps control disease progression. - Neoadjuvant therapy before surgery: may reduce tumor size to facilitate operative management.

Letrozole may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: discomfort in limbs and back. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain in the head. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, abdominal pain. - Bone fractures: due to decreased bone mineral density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Elevated cholesterol: significant rise in blood lipid levels.

Before initiating Letrozole therapy, several safety considerations are recommended. - Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Check liver function: perform baseline and periodic liver enzyme tests. - Evaluate lipid profile: monitor cholesterol levels during treatment. - Avoid use in premenopausal women: the drug is not indicated for this population. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent tamoxifen: antagonistic effect reduces therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower letrozole plasma concentrations. - Estrogen replacement therapy: diminishes the drug’s anti‑estrogenic action.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may increase INR, necessitating closer coagulation monitoring. - CYP2C19 inhibitors (e.g., fluconazole): can raise letrozole levels, watch for toxicity. - Statins metabolized by CYP3A4: monitor for muscle-related side effects.